Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript

What is happening is that the two other long-acting will just take part of the daily growth hormone. We never thought we actually face it having access to. And so our market penetration, our market share, our market value of SKYTROFA is basically unaffected to what we have seen. Go to — TransCon PTH and the US specific, the question you are providing me is — because our both Phase II and Phase III, which have — should be high retention and continue to have extremely high retention now on fourth or fifth years. I cannot remember now more. The problem is that I cannot really remember how many patients that is in Europe and US between the different trials. So therefore, in my numbers are a little bit weak in that, I would think it’s about 40-60 or something like that, but I’m not 100% sure about that.

So, please Scott can give you the number when he is finished here and send it to you.

Leland Gershell: Great. Thank you very much.

Operator: Thank you. And that’s all the time we have for questions and Q&A today. Thank you for your participation in today’s conference. This does conclude the program. You may now disconnect. Everyone, have a great day.

Jan Mikkelsen: Have a great day.